- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06094738
A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects
October 17, 2023 updated by: Corcept Therapeutics
A Phase 1, Randomized, Open-Label, Single-Dose, Three-Way Crossover Study to Evaluate The Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects
The primary objective of the study is to evaluate the effects of a high-fat meal and of a low-fat meal on the bioavailability of relacorilant in healthy subjects.
Study Overview
Status
Completed
Conditions
Detailed Description
Enrolled healthy male and female subjects will be randomized to receive 1 of 6 treatment sequences, each consisting of 3 treatments in 3 periods, in a crossover design.
The 3 treatments will be a single oral dose of relacorilant 400 mg 1) under fasted conditions, 2) after a high-fat meal, and 3) after a low-fat meal.
Each period will last 5 days, and a 7-day washout will follow Periods 1 and 2. Blood samples will be collected predose and at serial timepoints up to 4 days (Day 5) after dosing in each period for evaluation of the bioavailability of relacorilant.
Secondary objectives of the study will be evaluation of the bioavailability of relacorilant metabolites, and evaluation of safety and tolerability of relacorilant when administered to healthy subjects under fasted and fed conditions.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- inVentiv Health Clinical Research Services LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Body mass index >18.5 and <30.0 kg/m^2 and body weight ≥50.0 kg for male subjects and ≥45.0 kg for female subjects
- Healthy, as defined by the absence of clinically significant illness and/or surgery within 4 weeks prior to dosing, and the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease
- Female subjects of childbearing potential who are sexually active with a non-sterile male partner must be willing to use an acceptable contraceptive method as defined in the protocol, throughout the study.
- Male subjects who are not vasectomized for at least 6 months, and who are sexually active with a female partner of childbearing potential must be willing to use an acceptable contraceptive method as defined in the protocol, from the first study drug administration until at least 90 days after the last study drug administration
- Male subjects must be willing not to donate sperm until 90 days following the last study drug administration.
- Capable of, and have given, written informed consent
- Willing to consume a high-fat breakfast, including pork
- Able to and willing to fast for any laboratory evaluations.
Exclusion Criteria:
- Any clinically significant abnormality at physical examination, clinically significant abnormal laboratory test results or positive test for HIV, hepatitis B, or hepatitis C
- Female subject with a positive pregnancy test at Screening
- Male subject with a pregnant partner at Screening
- Positive urine drug screen or urine cotinine test or alcohol breath test at Screening
- History of allergic reactions to relacorilant or other related drugs, or to any excipient in the formulation
- Clinically significant electrocardiogram abnormalities or vital sign abnormalities at Screening
- History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit (more than 14 units of alcohol per week [1 unit = 83 mL of wine 12%, 200 mL of beer 5%, or 25 mL of alcohol 40%])
- History of significant drug abuse within 1 year prior to Screening or use of soft drugs within 3 months prior to Screening or hard drugs within 1 year of Screening
- Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration
- Use of medications for the timeframes specified in the protocol, with the exception of acceptable hormonal contraceptives and medications exempted by the Investigator, with agreement by the Sponsor because they are judged unlikely to affect the pharmacokinetic profile of the study drug or subject safety
- Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first dosing
- Have a condition that may be aggravated by glucocorticoid antagonism (eg, asthma, any chronic inflammatory condition). Subjects with inactive seasonal hay fever may be included. Subjects with childhood (aged less than 18 years) asthma may be included provided they have had no symptoms and required no treatment for at least 5 years.
- History of malabsorption syndrome or previous gastrointestinal surgery, which could affect drug absorption or metabolism, with the exception of appendectomy and cholecystectomy
- Pregnant or breast-feeding
- Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Relacorilant under fasted conditions
Subjects will receive oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 under fasted conditions.
The study period in which a subject will receive this treatment will be determined by random assignment to 1 of 6 treatment sequences.
|
Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 under fasted conditions
Other Names:
|
Experimental: Relacorilant after a high-fat meal
Subjects will receive oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a high-fat meal.
The study period in which a subject will receive this treatment will be determined by random assignment to 1 of 6 treatment sequences.
|
Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a high-fat meal
Other Names:
|
Experimental: Relacorilant after a low-fat meal
Subjects will receive oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a low-fat meal.
The study period in which a subject will receive this treatment will be determined by random assignment to 1 of 6 treatment sequences.
|
Oral relacorilant 400 mg (4 X 100 mg softgel capsules) single dose on Day 1 after a low-fat meal
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the concentration-time curve from time zero to the last observed concentration of plasma relacorilant (AUC0-t)
Time Frame: Predose and at serial timepoints up to 4 days (Day 5) after dosing on Day 1
|
Predose and at serial timepoints up to 4 days (Day 5) after dosing on Day 1
|
Area under the concentration-time curve from time zero extrapolated to infinity of plasma relacorilant (AUC0-inf)
Time Frame: Predose and at serial timepoints up to 4 days (Day 5) after dosing on Day 1
|
Predose and at serial timepoints up to 4 days (Day 5) after dosing on Day 1
|
Maximal observed concentration of plasma relacorilant (Cmax)
Time Frame: Predose and at serial timepoints up to 4 days (Day 5) after dosing on Day 1
|
Predose and at serial timepoints up to 4 days (Day 5) after dosing on Day 1
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC0-t of relacorilant plasma metabolites
Time Frame: Predose and at serial timepoints up to 4 days (Day 5) after dosing on Day 1
|
Predose and at serial timepoints up to 4 days (Day 5) after dosing on Day 1
|
AUC0-inf of relacorilant plasma metabolites
Time Frame: Predose and at serial timepoints up to 4 days (Day 5) after dosing on Day 1
|
Predose and at serial timepoints up to 4 days (Day 5) after dosing on Day 1
|
Cmax of relacorilant plasma metabolites
Time Frame: Predose and at serial timepoints up to 4 days (Day 5) after dosing on Day 1
|
Predose and at serial timepoints up to 4 days (Day 5) after dosing on Day 1
|
Number of subjects with one or more adverse events
Time Frame: Up to Day 28
|
Up to Day 28
|
Number of subjects with one or more serious adverse events
Time Frame: Up to Day 55
|
Up to Day 55
|
Number of subjects with one or more adverse events leading to study drug discontinuation
Time Frame: Up to Day 25
|
Up to Day 25
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Joseph Custodio, Corcept Therapeutics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 19, 2020
Primary Completion (Actual)
November 16, 2020
Study Completion (Actual)
November 16, 2020
Study Registration Dates
First Submitted
October 17, 2023
First Submitted That Met QC Criteria
October 17, 2023
First Posted (Actual)
October 23, 2023
Study Record Updates
Last Update Posted (Actual)
October 23, 2023
Last Update Submitted That Met QC Criteria
October 17, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CORT125134-129
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Relacorilant under fasted conditions
-
Corcept TherapeuticsCompleted
-
AstraZenecaQuintiles, Inc.CompletedSolid TumoursFrance, United Kingdom, Netherlands
-
Alyn Pediatric & Adolescent Rehabilitation HospitalUnknown
-
Sheba Medical CenterCompletedPhysiological StressIsrael
-
Atea Pharmaceuticals, Inc.RecruitingHealthy Volunteer StudyUnited States
-
Nexgen Pharma, IncCompleted
-
Leon BrüllHumboldt-Universität zu BerlinTerminatedFall Risk, Fall PreventionGermany
-
Steno Diabetes Center CopenhagenCompletedDiabetes Mellitus, Type 1 | ArrhythmiaDenmark
-
Sheba Medical CenterUnknown
-
SandozCompleted